

**bs-11554R****[ Primary Antibody ]****FAM126A Rabbit pAb****Bioss**  
**ANTIBODIES**

www.bioss.com.cn


sales@bioss.com.cn

techsupport@bioss.com.cn

400-901-9800

**— DATASHEET —**

<b>Host:</b> Rabbit <b>Clonality:</b> Polyclonal <b>GeneID:</b> 84668 <b>Target:</b> FAM126A <b>Immunogen:</b> KLH conjugated synthetic peptide derived from human FAM126A: 1-100/521. <b>Purification:</b> affinity purified by Protein A <b>Concentration:</b> 1mg/ml <b>Storage:</b> 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. Shipped at 4°C. Store at -20°C for one year. Avoid repeated freeze/thaw cycles. <b>Background:</b> Hyccin is a 521 amino acid cytoplasmic protein that is widely expressed with highest levels found in heart, brain, placenta, spleen and testis. Belonging to the FAM126 family, hyccin may play a role in the $\beta$ -catenin/Lef signaling pathway. Hyccin is likely involved in the process of myelination of the central and peripheral nervous system. Defects in the gene encoding hyccin are the cause of leukodystrophy hypomyelinating type 5 (HLD5), which is characterized by congenital cataract, progressive neurologic impairment and diffuse myelin deficiency. Individuals affected by HLD5 experience progressive pyramidal and cerebellar dysfunction along with muscle weakness in the lower limbs. Hyccin exists as two alternatively spliced isoforms and is encoded by a gene located on human chromosome 7.	<b>Isotype:</b> IgG <b>SWISS:</b> Q9BYI3 <b>Applications:</b> WB (1:500-2000)  <b>Reactivity:</b> Human, Mouse (predicted: Rat, Rabbit, Pig, Dog, Horse)  <b>Predicted MW.:</b> 58 kDa  <b>Subcellular Location:</b> Cell membrane ,Cytoplasm
--	--

**— VALIDATION IMAGES —**

Sample: Heart (Mouse) Lysate at 40 ug Primary:  
Anti-FAM126A (bs-11554R) at 1/300 dilution  
Secondary: IRDye800CW Goat Anti-Rabbit IgG at  
1/20000 dilution Predicted band size: 58 kD  
Observed band size: 58 kD

**— SELECTED CITATIONS —**

- **[IF=11.6]** Xiuxing Jiang. et al. Targeting PI4KA sensitizes refractory leukemia to chemotherapy by modulating the ERK/AMPK/OXPHOS axis.. THERANOSTICS. 2022 Oct;12(16):6972-6988 WB ;Human. 36276647